Simulation Guided Trial Design: Designing a Phase 3 Group Sequential Trial

Designing a group sequential phase 3 with a long time to final endpoint, using longitudinal modelling and Bayesian predictive probabilities for decision making at the interims.

Designing a trial with three arms compared to placebo and Active Comparator, using two endpoints: an early endpoint to compare to PBO for futility & arm selection in phase 2, and a late efficacy endpoint to compare against the AC.

Designing a platform trial to test several assets in the same indication that will become available over time.

Designing a phase 2 trial to determine for which of four rare tumours a treatment is effective. Looking at separate analyses, pooled analysis and using a hierarchical model to borrow across groups.

As part of our 2025 Simulation Guided Trial Design series, Kert Viele designs a Phase II trial with multiple dose strengths using a dose response model in this webinar.

Tom Parke presents two simple Phase II trials in this Simulation Guided Trial Design webinar. In the first trial example, he designs a Phase II trial with two arms and stopping for futility. In the second example, he designs a Phase II trial with three arms and arm dropping.

In this webinar that is a part of our 2025 Simulation Guided Trial Design series, Elias Meyer designs an advanced Phase I trial that includes open enrollment, backfilling, and targeting efficacy as well as toxicity.

As part of our 2025 Simulation Guided Trial Design series, in this webinar Tom Parke designs a classic Phase I trial using i3+3, BOIN, m-TPI-2 methods or CRM (Continuous Re-assessment Method using Bayesian logistic regression).

In this first webinar of our 2025 Simulation Guided Trial Design series, Scott Berry covers the background and importance of simulations in clinical trial designs.

In this FACTS webinar, Tom Parke provides a comprehensive comparison of modern dose escalation methods in clinical trials, focusing on their implementation and performance within the FACTS software.

Tom Parke, Director of Software Solutions at Berry Consultants, introduces some of the new features in the FACTS 7.2 release.

In this FACTS webinar, Nick Berry, Senior Statistical Scientist, takes us through how longitudinal models work within the FACTS software.

In this FACTS webinar, the Berry Consultants team unveils FACTS 7.1.1, showcasing important updates to our statistical software for clinical trial design.